Holen Sie sich die Stockscreener-App
40.32
2.84%
-1.1985
Uniqure Nv Aktie (QURE) Neueste Nachrichten
uniQure's Huntington's prospects brighten after FDA shift - S&P Global
If You Invested $1,000 in Uniqure (QURE) - Stock Titan
The Technical Signals Behind (QURE) That Institutions Follow - Stock Traders Daily
What Caused uniQure's Dramatic Stock Plunge - Kavout | AI
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
UniQure soars as Cantor upgrades on plans to seek gene therapy nod - MSN
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Uniqure Insider Sold Shares Worth $952,051, According to a Recent SEC Filing - Moomoo
uniQure (QURE) CEO sells 21,082 shares after option exercise under 10b5-1 plan - Stock Titan
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Price to sales forward of uniQure N.V. – FWB:UQ1 - TradingView
UniQure surges on plans to seek US nod for gene therapy - MSN
QURE Investors Have Opportunity to Lead uniQure N.V. Class Action - The National Law Review
Uniqure Insider Sold Shares Worth $983,030, According to a Recent SEC Filing - Moomoo
uniQure (QURE) CMO sells 30,000 shares and exercises 10,000 stock options - Stock Titan
uniQure (QURE) director sells 21,167 shares after exercising options - Stock Titan
UniQure (NASDAQ: QURE) affiliate plans 21,082-share option sale; June open-market sales listed - Stock Titan
Precision Trading with Uniqure N.v. (QURE) Risk Zones - Stock Traders Daily
Price to earnings forward of uniQure N.V. – NASDAQ:QURE - TradingView
Price to earnings forward of uniQure N.V. – LSE:0EE0 - TradingView
uniQure (QURE) Now Trades Above Golden Cross: Time to Buy? - Yahoo Finance
QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure - Stocktwits
Form 144 uniQure N.V. For: 30 June - Investing.com UK
Why Did QURE Stock Almost Halve Pre-Market Today? - Stocktwits
Form 144 uniQure N.V. For: 30 June By Investing.com - Investing.com Nigeria
uniQure (QURE) CMO auto-sells shares for RSU tax withholding, keeps stake - Stock Titan
UniQure (NASDAQ: QURE) files Form 144 to sell 30,000 shares via Citigroup - Stock Titan
UniQure (NASDAQ: QURE) insider notice to sell 21,167 shares - Stock Titan
Price to book forward of uniQure N.V. – SWB:UQ1 - TradingView
uniQure N.V. moves ahead with $225 million public offering. Capital raise reshapes the gene therapy - AD HOC NEWS
uniQure N.V. (QURE) Investors: Kessler Topaz Meltzer & Check, LLP - The National Law Review
QURE Maintained by HC Wainwright & Co. -- Price Target Raised to $80 - GuruFocus
Enterprise value to EBITDA forward of uniQure N.V. – SWB:UQ1 - TradingView
Enterprise value to revenue forward of uniQure N.V. – SWB:UQ1 - TradingView
Price to sales forward of uniQure N.V. – GETTEX:UQ1 - TradingView
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $80 - 富途牛牛
Bronstein, Gewirtz & Grossman, LLC Is Investigating uniQure N.V. (QURE) And Encourages Stockholders to Connect - The National Law Review
Price to earnings forward of uniQure N.V. – BMV:QURE/N - TradingView
uniQure N.V. Actuals & Estimates (LSE:0EE0) - TradingView
uniQure N.V. Actuals & Estimates (BX:UQ1) - TradingView
Form 144 uniQure N.V. For: 26 June By Investing.com - Investing.com South Africa
Form 144 uniQure N.V. For: 26 June - Investing.com UK
uniQure NV | 4: Statement of changes in beneficial ownership of securities-Officer Kapusta Matthew C - Moomoo
uniQure (QURE) CEO Kapusta sells 35K shares after exercising options - Stock Titan
UniQure (QURE) files Rule 144 to sell 22,402 RSU shares; prior 45,000 sold - Stock Titan
uniQure NV | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Enterprise value to EBIT forward of uniQure N.V. – NASDAQ:QURE - TradingView
uniQure N.V. Actuals & Estimates (FWB:UQ1) - TradingView
QURE Maintained by Mizuho -- Price Target Raised to $68.00 - GuruFocus
uniQure Epilepsy Gene Therapy Data Draws Investor Focus - Streetwise Reports
Gene Therapy Co. Announces Initial Data for Refractory Epilepsy Treatment Gets Buy Rating - Streetwise Reports
0.78%
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):